SomaLogic
2945 Wilderness Place, Boulder, CO, 80301, United States
Overview
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 8
Sector focus
- Biotechnology
- Health Care
- Health Diagnostics
- Medical Device
Investment portfolio
- SomaLogic
Participated · Series A · Dec 2020
SomaLogic develops and commercializes a proprietary proteomics platform built around its SOMAmer protein-binding reagents, which blend attributes of monoclonal antibodies and traditional aptamers. Its flagship SOMAscan assay currently deploys 1,310 different SOMAmer reagents to quantify proteins across a broad concentration range using small sample volumes from multiple biological matrices. These capabilities provide researchers and clinicians with powerful tools for protein biomarker discovery, diagnostics development, and pharmaceutical innovation. The company is led by Chief Executive Officer Byron Hewett and Founder & Chairman Larry Gold, PhD. SomaLogic plans to expand its portfolio of life-science tools and clinical diagnostic products that leverage its core technology. To finance this growth, it is arranging up to $60.5 million in combined debt and equity financing from Visium Healthcare Partners, strengthening its balance sheet for continued R&D and commercialization efforts.